<!doctype html><html lang="en-US"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1"><title>Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People - Transfeminine Science</title><link rel="preload" href="../../assets/images/branding/logo.png" as="image" /><link rel="preload" href="../../assets/images/branding/logo-dark.png" as="image" /><link rel="stylesheet" href="../../assets/css/vendor/normalize.css"><link rel="stylesheet" href="../../assets/css/variables.css"><link rel="stylesheet" href="../../assets/css/site-layout.css"><link rel="stylesheet" href="../../assets/css/article-content.css"><link rel="stylesheet" href="../../assets/css/print.css"><link rel="stylesheet" href="../../assets/css/hover-refs.css"><meta name="robots" content="noarchive"><link rel="apple-touch-icon" sizes="180x180" href="../../apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="../../favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="../../favicon-16x16.png"><link rel="icon" href="../../favicon.ico"><link rel="manifest" href="../../site.webmanifest"><meta name="msapplication-TileColor" content="#ece5ff"><meta name="theme-color" content="#ffffff"><link type="application/atom+xml" rel="alternate" href="../../feed-posts.xml" title="Transfeminine Science" /><link rel="alternate" type="application/atom+xml" title="Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People - Transfeminine Science" href="../../feed.xml"><link rel="canonical" href="index.html" /><meta property="og:title" content="Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People" /><meta property="og:image" content="https://transfemscience.org/assets/images/branding/logo-alt.png" /><meta name="twitter:image" content="https://transfemscience.org/assets/images/branding/logo-alt.png" /><meta property="og:url" content="https://transfemscience.org/articles/sublingual-ev/" /><meta property="og:locale" content="en_US" /><meta property="og:site_name" content="Transfeminine Science" /><meta property="og:type" content="article" /><meta name="twitter:card" content="summary" /><meta name="publisher" content="Transfeminine Science"><meta name="description" content="Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People by Aly" /><meta property="og:description" content="Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People by Aly" /><meta name="author" content="Aly" /><meta name="citation_author" content="Aly"><meta name="citation_title" content="Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People"><meta name="citation_publication_date" content="2019/01/05"><meta name="citation_journal_title" content="Transfeminine Science"><meta name="citation_fulltext_html_url" content="https://transfemscience.org/articles/sublingual-ev/"> <script type="application/ld+json"> { "@context": "https://schema.org", "name": "Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People", "mainEntityOfPage": "https://transfemscience.org/articles/sublingual-ev/", "headline": "Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People", "url": "https://transfemscience.org/articles/sublingual-ev/", "isAccessibleForFree": "True", "description": "Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People by Aly", "@type": "MedicalScholarlyArticle", "dateModified": "2022-11-28", "datePublished": "2019-01-05", "author": { "@type": "Person", "name": "Aly", "email": "", "url": "https://transfemscience.org/about/#aly" }, "publisher": { "@type": "Organization", "name": "Transfeminine Science", "url": "https://transfemscience.org", "email": "", "logo": "https://transfemscience.org/assets/images/branding/logo.png" } } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://transfemscience.org/" }, { "@type": "ListItem", "position": 2, "name": "Articles", "item": "https://transfemscience.org/articles/" }, { "@type": "ListItem", "position": 3, "name": "Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People" } ] }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://transfemscience.org/" }, { "@type": "ListItem", "position": 2, "name": "Articles", "item": "https://transfemscience.org/articles/" }, { "@type": "ListItem", "position": 3, "name": "Articles by Date", "item": "https://transfemscience.org/articles-by-date/" }, { "@type": "ListItem", "position": 4, "name": "Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People" } ] } </script> <script src="../../assets/js/script.js"></script> <script src="../../assets/js/hover-refs.js" defer></script></head><body> <svg xmlns="http://www.w3.org/2000/svg" style="display: none;"> <symbol id="svg-link" viewBox="0 0 24 24"><title>Link</title><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="feather feather-link"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path> </svg> </symbol> </svg><div id="header"><div id="header-subcontainer"> <a href="../../index.html" id="site-icon-and-title-container"> <span id="site-icon">&nbsp;</span> <span id="site-title" translate="no" class="notranslate"> <span id="site-title-text-xs">TFS</span> <span id="site-title-text-sm">TFSci</span> <span id="site-title-text-md">Transfem Sci</span> <span id="site-title-text-lg">Transfeminine Science</span> </span> </a> <span id="top-links"> <a href="../index.html" class="top-link">Articles</a> <a href="../../articles-by-date/index.html" class="top-link">Latest</a> <a href="../../misc/index.html" class="top-link">Misc</a> <a href="../../about/index.html" class="top-link">About</a> </span> <span id="top-buttons"> <button id="theme-button" class="top-button" title="Theme (light/dark)"> <svg id="theme-button-light-svg" class="top-button-svg" width="20" height="20" viewBox="0 0 32 32"><path d="M16 12.005a4 4 0 1 1-4 4a4.005 4.005 0 0 1 4-4m0-2a6 6 0 1 0 6 6a6 6 0 0 0-6-6z"></path><path d="M5.394 6.813l1.414-1.415l3.506 3.506L8.9 10.318z"></path><path d="M2 15.005h5v2H2z"></path><path d="M5.394 25.197L8.9 21.691l1.414 1.415l-3.506 3.505z"></path><path d="M15 25.005h2v5h-2z"></path><path d="M21.687 23.106l1.414-1.415l3.506 3.506l-1.414 1.414z"></path><path d="M25 15.005h5v2h-5z"></path><path d="M21.687 8.904l3.506-3.506l1.414 1.415l-3.506 3.505z"></path><path d="M15 2.005h2v5h-2z"></path></svg> <svg id="theme-button-dark-svg" class="top-button-svg" width="20" height="20" viewBox="0 0 32 32"><path d="M13.502 5.414a15.075 15.075 0 0 0 11.594 18.194a11.113 11.113 0 0 1-7.975 3.39c-.138 0-.278.005-.418 0a11.094 11.094 0 0 1-3.2-21.584M14.98 3a1.002 1.002 0 0 0-.175.016a13.096 13.096 0 0 0 1.825 25.981c.164.006.328 0 .49 0a13.072 13.072 0 0 0 10.703-5.555a1.01 1.01 0 0 0-.783-1.565A13.08 13.08 0 0 1 15.89 4.38A1.015 1.015 0 0 0 14.98 3z"></path></svg> </button> <button id="language-button" class="top-button" title="Translate"> <svg class="top-button-svg" xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24"><path d="M12.65 15.67c.14-.36.05-.77-.23-1.05l-2.09-2.06.03-.03c1.74-1.94 2.98-4.17 3.71-6.53h1.94c.54.0.99-.45.99-.99v-.02c0-.54-.45-.99-.99-.99H10V3c0-.55-.45-1-1-1s-1 .45-1 1v1H1.99c-.54.0-.99.45-.99.99.0.55.45.99.99.99h10.18C11.5 7.92 10.44 9.75 9 11.35c-.81-.89-1.49-1.86-2.06-2.88-.16-.29-.45-.47-.78-.47-.69.0-1.13.75-.79 1.35.63 1.13 1.4 2.21 2.3 3.21L3.3 16.87c-.4.39-.4 1.03.0 1.42.39.39 1.02.39 1.42.0L9 14l2.02 2.02c.51.51 1.38.32 1.63-.35zM17.5 10c-.6.0-1.14.37-1.35.94l-3.67 9.8c-.24.61.22 1.26.87 1.26.39.0.74-.24.88-.61l.89-2.39h4.75l.9 2.39c.14.36.49.61.88.61.65.0 1.11-.65.88-1.26l-3.67-9.8c-.22-.57-.76-.94-1.36-.94zm-1.62 7 1.62-4.33L19.12 17h-3.24z"></path></svg> </button> <button id="search-button" class="top-button" title="Search"> <svg version="1.1" class="top-button-svg" width="24" height="24" viewBox="0 0 32 32" xmlns="http://www.w3.org/2000/svg" xmlns:sketch="http://www.bohemiancoding.com/sketch/ns" xmlns:xlink="http://www.w3.org/1999/xlink"><g><path d="M19.4271164,21.4271164 C18.0372495,22.4174803 16.3366522,23 14.5,23 C9.80557939,23 6,19.1944206 6,14.5 C6,9.80557939 9.80557939,6 14.5,6 C19.1944206,6 23,9.80557939 23,14.5 C23,16.3366522 22.4174803,18.0372495 21.4271164,19.4271164 L27.0119176,25.0119176 C27.5621186,25.5621186 27.5575313,26.4424687 27.0117185,26.9882815 L26.9882815,27.0117185 C26.4438648,27.5561352 25.5576204,27.5576204 25.0119176,27.0119176 L19.4271164,21.4271164 L19.4271164,21.4271164 Z M14.5,21 C18.0898511,21 21,18.0898511 21,14.5 C21,10.9101489 18.0898511,8 14.5,8 C10.9101489,8 8,10.9101489 8,14.5 C8,18.0898511 10.9101489,21 14.5,21 L14.5,21 Z"></path></g></svg> </button> <button id="toc-button-mobile" class="top-button" title="Article contents (Ctrl+Shift+L)"> <svg class="top-button-svg" xmlns="http://www.w3.org/2000/svg" version="1.0" width="16" height="16" viewBox="0 0 16 16"><g transform="translate(0,16) scale(0.002536,-0.002540)"><path d="M550 6274 c-81 -17 -207 -79 -282 -139 -110 -87 -202 -230 -238 -371 -20 -76 -20 -122 -20 -2618 0 -2810 -5 -2597 65 -2741 87 -180 227 -304 420 -372 l80 -28 2551 -3 2551 -2 98 25 c253 64 441 251 506 503 19 73 19 137 19 2617 0 2478 0 2544 -19 2617 -51 198 -181 361 -361 451 -53 26 -126 54 -165 62 -103 21 -5105 21 -5205 -1z m5055 -3129 l0 -2440 -2447 -3 -2448 -2 0 2445 0 2445 2448 -2 2447 -3 0 -2440z" /><path d="M1410 4893 c0 -2 0 -158 0 -348 l-1 -346 346 0 346 0 0 346 0 346 -346 2 c-190 1 -345 1 -345 0z" /><path d="M2460 4893 c0 -2 0 -158 0 -348 l-1 -345 1221 0 1221 0 0 345 0 345 -1221 3 c-671 1 -1220 1 -1220 0z" /><path d="M1407 3493 c-1 -1 -1 -157 1 -347 l3 -346 344 0 345 0 0 340 c0 187 0 342 0 345 0 5 -689 13 -693 8z" /><path d="M2457 3493 c-1 -1 -1 -157 1 -347 l3 -346 1219 0 1220 0 0 340 c0 187 -1 342 -2 345 -3 4 -2437 13 -2441 8z" /><path d="M1409 2096 c-2 -2 -3 -160 -1 -350 l3 -346 344 0 344 0 3 346 c2 190 1 348 -1 350 -6 5 -686 5 -692 0z" /><path d="M2459 2096 c-2 -2 -3 -160 -1 -350 l3 -346 1219 0 1219 0 3 346 c2 190 1 348 -1 350 -6 5 -2436 5 -2442 0z" /></g></svg> </button> <button id="menu-button-mobile-menu" class="top-button" title="Menu"> <svg class="top-button-svg" xmlns="http://www.w3.org/2000/svg" width="21" height="21" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"><path d="M 3,12 L 21,12" /><path d="M 3,6 L 21,6" /><path d="M 3,18 L 21,18" /></svg> </button> <button id="hide-persistent-header-button" class="top-button" title="Hide top bar (Ctrl+Shift+H)"> <svg id="hide-persistent-header-button-svg" version="1.1" x="0px" y="0px" width="20px" height="20px" viewBox="0 0 24 24" enable-background="new 0 0 24 24" xml:space="preserve" fill="#5F6368"><path d="M8.59,16.59L13.17,12L8.59,7.41L10,6l6,6l-6,6L8.59,16.59z"></path><path fill="none" d="M0,0h24v24H0V0z"></path></svg> </button> </span></div><div id="mobile-menu"> <span id="top-links-mobile"> <a href="../index.html" class="top-link">Articles</a> <a href="../../articles-by-date/index.html" class="top-link">Latest</a> <a href="../../misc/index.html" class="top-link">Misc</a> <a href="../../about/index.html" class="top-link">About</a> </span></div></div><button id="restore-persistent-header-button" class="top-button" title="Show top bar (Ctrl+Shift+H)"> <svg id="restore-persistent-header-button-svg" version="1.1" x="0px" y="0px" width="20px" height="20px" viewBox="0 0 24 24" enable-background="new 0 0 24 24" xml:space="preserve" fill="#5F6368"><path d="M8.59,16.59L13.17,12L8.59,7.41L10,6l6,6l-6,6L8.59,16.59z"></path><path fill="none" d="M0,0h24v24H0V0z"></path></svg> </button> <button id="sidebar-button-standalone" class="sidebar-button" title="Article contents (Ctrl+Shift+L)"> <span id="sidebar-button-standalone-icon" class="sidebar-button-icon"> <svg id="sidebar-button-standalone-icon-svg" class="sidebar-button-icon-svg" xmlns="http://www.w3.org/2000/svg" version="1.0" width="16" height="16" viewBox="0 0 16 16"><g transform="translate(0,16) scale(0.002536,-0.002540)"><path d="M550 6274 c-81 -17 -207 -79 -282 -139 -110 -87 -202 -230 -238 -371 -20 -76 -20 -122 -20 -2618 0 -2810 -5 -2597 65 -2741 87 -180 227 -304 420 -372 l80 -28 2551 -3 2551 -2 98 25 c253 64 441 251 506 503 19 73 19 137 19 2617 0 2478 0 2544 -19 2617 -51 198 -181 361 -361 451 -53 26 -126 54 -165 62 -103 21 -5105 21 -5205 -1z m5055 -3129 l0 -2440 -2447 -3 -2448 -2 0 2445 0 2445 2448 -2 2447 -3 0 -2440z" /><path d="M1410 4893 c0 -2 0 -158 0 -348 l-1 -346 346 0 346 0 0 346 0 346 -346 2 c-190 1 -345 1 -345 0z" /><path d="M2460 4893 c0 -2 0 -158 0 -348 l-1 -345 1221 0 1221 0 0 345 0 345 -1221 3 c-671 1 -1220 1 -1220 0z" /><path d="M1407 3493 c-1 -1 -1 -157 1 -347 l3 -346 344 0 345 0 0 340 c0 187 0 342 0 345 0 5 -689 13 -693 8z" /><path d="M2457 3493 c-1 -1 -1 -157 1 -347 l3 -346 1219 0 1220 0 0 340 c0 187 -1 342 -2 345 -3 4 -2437 13 -2441 8z" /><path d="M1409 2096 c-2 -2 -3 -160 -1 -350 l3 -346 344 0 344 0 3 346 c2 190 1 348 -1 350 -6 5 -686 5 -692 0z" /><path d="M2459 2096 c-2 -2 -3 -160 -1 -350 l3 -346 1219 0 1219 0 3 346 c2 190 1 348 -1 350 -6 5 -2436 5 -2442 0z" /></g></svg> </span> </button><div id="mid-section"><div id="sidebar"><div id="sidebar-subcontainer"><div id="sidebar-title-container"> <button id="sidebar-button" class="sidebar-button" title="Article contents (Ctrl+Shift+L)"> <span class="sidebar-button-icon"> <svg class="sidebar-button-icon-svg" xmlns="http://www.w3.org/2000/svg" version="1.0" width="16" height="16" viewBox="0 0 16 16"><g transform="translate(0,16) scale(0.002536,-0.002540)"><path d="M550 6274 c-81 -17 -207 -79 -282 -139 -110 -87 -202 -230 -238 -371 -20 -76 -20 -122 -20 -2618 0 -2810 -5 -2597 65 -2741 87 -180 227 -304 420 -372 l80 -28 2551 -3 2551 -2 98 25 c253 64 441 251 506 503 19 73 19 137 19 2617 0 2478 0 2544 -19 2617 -51 198 -181 361 -361 451 -53 26 -126 54 -165 62 -103 21 -5105 21 -5205 -1z m5055 -3129 l0 -2440 -2447 -3 -2448 -2 0 2445 0 2445 2448 -2 2447 -3 0 -2440z" /><path d="M1410 4893 c0 -2 0 -158 0 -348 l-1 -346 346 0 346 0 0 346 0 346 -346 2 c-190 1 -345 1 -345 0z" /><path d="M2460 4893 c0 -2 0 -158 0 -348 l-1 -345 1221 0 1221 0 0 345 0 345 -1221 3 c-671 1 -1220 1 -1220 0z" /><path d="M1407 3493 c-1 -1 -1 -157 1 -347 l3 -346 344 0 345 0 0 340 c0 187 0 342 0 345 0 5 -689 13 -693 8z" /><path d="M2457 3493 c-1 -1 -1 -157 1 -347 l3 -346 1219 0 1220 0 0 340 c0 187 -1 342 -2 345 -3 4 -2437 13 -2441 8z" /><path d="M1409 2096 c-2 -2 -3 -160 -1 -350 l3 -346 344 0 344 0 3 346 c2 190 1 348 -1 350 -6 5 -686 5 -692 0z" /><path d="M2459 2096 c-2 -2 -3 -160 -1 -350 l3 -346 1219 0 1219 0 3 346 c2 190 1 348 -1 350 -6 5 -2436 5 -2442 0z" /></g></svg> </span> </button> <span id="sidebar-title">Contents</span></div><div id="sidebar-contents"><div class="toc-h1"><a id="heading-0" href="index.html#top" class="toc-link">Top of page</a><div><div class="toc-h2"><a id="heading-1" href="index.html#abstract--tldr" class="toc-link">Abstract / TL;DR</a></div><div class="toc-h2"><a id="heading-2" href="index.html#introduction" class="toc-link">Introduction</a></div><div class="toc-h2"><a id="heading-3" href="index.html#effectiveness-of-sublingual-estradiol-valerate" class="toc-link">Effectiveness of Sublingual Estradiol Valerate</a></div><div class="toc-h2"><a id="heading-4" href="index.html#formulation-of-estradiol-and-estradiol-valerate-tablets-and-implications-for-sublingual-use" class="toc-link">Formulation of Estradiol and Estradiol Valerate Tablets and Implications for Sublingual Use</a><div><div class="toc-h3"><a id="heading-5" href="index.html#micronization-of-oral-estradiol-valerate-tablets" class="toc-link">Micronization of Oral Estradiol Valerate Tablets</a></div><div class="toc-h3"><a id="heading-6" href="index.html#physicochemical-properties-of-estradiol-versus-estradiol-valerate" class="toc-link">Physicochemical Properties of Estradiol versus Estradiol Valerate</a></div><div class="toc-h3"><a id="heading-7" href="index.html#formulation-and-dissolution-of-oral-estradiol-valerate-tablets" class="toc-link">Formulation and Dissolution of Oral Estradiol Valerate Tablets</a></div></div></div><div class="toc-h2"><a id="heading-8" href="index.html#estradiol-or-estradiol-valerate-for-sublingual-use" class="toc-link">Estradiol or Estradiol Valerate for Sublingual Use?</a></div><div class="toc-h2"><a id="heading-9" href="index.html#references" class="toc-link">References</a></div></div></div></div></div></div><div id="main-area"><div id="article"><h1 id="sublingual-administration-of-oral-estradiol-valerate-tablets-for-transfeminine-people"> <a href="index.html#sublingual-administration-of-oral-estradiol-valerate-tablets-for-transfeminine-people" aria-labelledby="sublingual-administration-of-oral-estradiol-valerate-tablets-for-transfeminine-people" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People</h1><p>By <a href="../../about/index.html#aly">Aly</a> | First published January 5, 2019 | Last modified November 28, 2022</p><h2 id="abstract--tldr"> <a href="index.html#abstract--tldr" aria-labelledby="abstract--tldr" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Abstract / TL;DR</h2><p>Oral estradiol tablets can be taken sublingually instead of orally and this allows for greater bioavailability and higher estradiol levels than with oral use. For this reason, sublingual estradiol is frequently used in transfeminine people. Oral estradiol valerate tablets also exist in some parts of the world and it’s often inquired by transfeminine people whether this form of estradiol is likewise effective sublingually. Research in this area is limited and no direct comparisons exist, but at least one study in cisgender women has shown that oral estradiol valerate tablets taken sublingually can result in high estradiol levels and gonadal suppression analogously to sublingual estradiol. In addition, at least one gender-affirming hormone therapy clinic has reported use of sublingual estradiol valerate in transfeminine people. Hence, sublingual estradiol valerate appears to be an effective means of estradiol delivery similarly to sublingual estradiol. One difference between these forms of estradiol is that estradiol valerate contains less estradiol than estradiol by weight and hence should be taken at slightly higher doses. While they can be effective, oral estradiol tablets and oral estradiol valerate tablets were not intended or designed for sublingual use, and formulations of these tablets vary. The implications of this in terms of clinical properties, if any, are unknown. However, it does seem apparent that different tablet formulations may require substantially different amounts of time to dissolve when used sublingually. As a result, some formulations of oral estradiol and oral estradiol valerate may be better-suited for sublingual use than others. Additional characteristics of these formulations like micronization and lipophilicity could also differentially influence their pharmacokinetics in ways that have not been studied. It may be advisable to choose sublingual estradiol over sublingual estradiol valerate where possible simply because sublingual estradiol is much better-characterized in comparison and there are fewer unknowns with it. However, sublingual estradiol valerate can be a clearly effective form of estradiol for transfeminine people as well if needed.</p><h2 id="introduction"> <a href="index.html#introduction" aria-labelledby="introduction" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Introduction</h2><p>Oral <a href="https://en.wikipedia.org/wiki/Estradiol_(medication)">estradiol</a> tablets (e.g., Estrace and Estrofem among other brand names) are indicated for <a href="https://en.wikipedia.org/wiki/Oral_administration">oral administration</a> (i.e., taken by mouth/swallowed) and this is how they are normally taken. As an alternative to the standard oral route however, these tablets can be taken <a href="https://en.wikipedia.org/wiki/Sublingual_administration">sublingually</a> (held under the tongue) or <a href="https://en.wikipedia.org/wiki/Buccal_administration">buccally</a> (held in the cheek or lips/gums). Sublingual or buccal administration of oral estradiol tablets allows for much greater <a href="https://en.wikipedia.org/wiki/Bioavailability">bioavailability</a> and estradiol levels in comparison to oral administration (<a href="../sublingual-e2-transfem/index.html">Sam, 2021</a>; <a href="https://en.wikipedia.org/wiki/Pharmacokinetics_of_estradiol#Sublingual_administration">Wiki</a>; <a href="https://en.wikipedia.org/wiki/Template:Hormone_levels_with_sublingual_estradiol">Graphs</a>; <a href="https://en.wikipedia.org/wiki/Pharmacokinetics_of_estradiol#Buccal_administration">Wiki</a>). Transfeminine people often use sublingual estradiol as the estrogen component of hormone therapy. In various countries, for instance many European countries, estradiol is also provided in oral form as <a href="https://en.wikipedia.org/wiki/Estradiol_valerate">estradiol valerate</a> (EV) tablets (e.g., Progynova among other brand names). It is frequently inquired by transfeminine people whether estradiol valerate tablets can be taken sublingually similarly to estradiol tablets and whether there are any differences between these two estradiol forms for this route. This article is intended to explore and shed some light on these questions.</p><h2 id="effectiveness-of-sublingual-estradiol-valerate"> <a href="index.html#effectiveness-of-sublingual-estradiol-valerate" aria-labelledby="effectiveness-of-sublingual-estradiol-valerate" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Effectiveness of Sublingual Estradiol Valerate</h2><p>Estradiol valerate is an <a href="https://en.wikipedia.org/wiki/Estrogen_ester">estradiol ester</a> and a <a href="https://en.wikipedia.org/wiki/Prodrug">prodrug</a> of estradiol. Estradiol esters themselves are <a href="http://en.wikipedia.org/wiki/Biological_activity">pharmacologically inactive</a> prior to conversion into estradiol. Estradiol valerate and other related estradiol esters are <a href="https://en.wikipedia.org/wiki/Bond_cleavage">cleaved</a> into estradiol by various <a href="https://en.wikipedia.org/wiki/Esterase">esterase</a> <a href="https://en.wikipedia.org/wiki/Enzyme">enzymes</a>. These esterases are widely expressed throughout the body, and the <a href="https://en.wikipedia.org/wiki/Biotransformation">metabolism</a> of estradiol esters into estradiol occurs not only in the liver but has also been shown to take place rapidly in blood and other tissues (<a href="https://en.wikipedia.org/wiki/Estradiol_valerate#Pharmacokinetics">Wiki</a>). Hence, estradiol esters like estradiol valerate do not require the <a href="https://en.wikipedia.org/wiki/Liver">first pass</a> through the liver that occurs with oral administration to become pharmacologically active as estrogens. As such, transformation of estradiol valerate into estradiol should not be an impediment in terms of non-oral administration of estradiol valerate, for instance via sublingual administration (as well as in the form of <a href="https://en.wikipedia.org/wiki/Pharmacokinetics_of_estradiol#Intramuscular_injection">depot injectables</a> of course).</p><p>Studies of estradiol tablets administered sublingually instead of orally are limited, and studies on estradiol valerate tablets used sublingually are extremely scarce. No direct comparisons have been made between sublingual use of estradiol tablets versus sublingual use of estradiol valerate tablets. Hence, we currently don’t have reliable data on how sublingual estradiol valerate compares to sublingual estradiol in terms of <a href="https://en.wikipedia.org/wiki/Pharmacokinetics">pharmacokinetics</a> (e.g., bioavailability, estradiol levels, <a href="https://en.wiktionary.org/wiki/concentration-time_curve">concentration–time curve</a>, etc.).</p><p>Only one study seems to have researched and characterized sublingual administration of oral estradiol valerate tablets. This study assessed the use of oral estradiol valerate tablets (brand name Progynova [Schering]) administered sublingually 3 to 4 times per day in a group of <a href="https://en.wikipedia.org/wiki/Premenopause">premenopausal</a> cisgender women. The researchers reported the findings of their study in the following two publications:</p><ul><li>Serhal, P., &amp; Craft, I. (1989). Oocyte donation in 61 patients. <em>The Lancet</em>, <em>333</em>(8648), 1185–1187. [DOI:<a href="https://doi.org/10.1016/S0140-6736(89)92762-1">10.1016/S0140-6736(89)92762-1</a>]</li><li>Serhal, P. (1990). Oocyte donation and surrogacy. <em>British Medical Bulletin</em>, <em>46</em>(3), 796–812. [DOI:<a href="https://doi.org/10.1093/oxfordjournals.bmb.a072432">10.1093/oxfordjournals.bmb.a072432</a>]</li></ul><p>The results in terms of hormone levels with sublingual estradiol valerate were as follows (top plot is a control <a href="https://en.wikipedia.org/wiki/Menstrual_cycle">menstrual cycle</a> in untreated women, bottom plot is a cycle with sublingual estradiol valerate):</p><div class="table-wrapper"><table><thead><tr><th><img src="https://upload.wikimedia.org/wikipedia/commons/0/0c/Hormone_levels_with_oral_estradiol_valerate_tablets_%28Progynova%29_taken_sublingually_in_premenopausal_women.png" alt="" /></th></tr></thead><tbody><tr><td><strong>Figure 1:</strong> Levels of estradiol (E2), <a href="https://en.wikipedia.org/wiki/Progesterone">progesterone</a> (P4), <a href="https://en.wikipedia.org/wiki/Luteinizing_hormone">luteinizing hormone</a> (LH), and <a href="https://en.wikipedia.org/wiki/Follicle-stimulating_hormone">follicle-stimulating hormone</a> (FSH) with 2 mg oral micronized estradiol valerate tablets (Progynova) administered sublingually (SL) 3 or 4 times per day in a group of premenopausal women (bottom). The normal menstrual cycle in a control group of premenopausal women is also shown (top). The time of blood collection following administration was not specified.</td></tr></tbody></table></div><p>As can be seen in the figure, estradiol levels with sublingual estradiol valerate were much higher than in normally cycling control women. In addition, levels of other hormones were suppressed, which is in accordance with the high estradiol levels exhibiting negative feedback on the <a href="https://en.wikipedia.org/wiki/Hypothalamic%E2%80%93pituitary%E2%80%93gonadal_axis">hypothalamic–pituitary–gonadal axis</a> and suppressing hormone production. These findings indicate that sublingual estradiol valerate is well-absorbed and is able to achieve high estradiol levels analogously to sublingual estradiol. In other words, although we still don’t have direct comparisons between the two, sublingual estradiol valerate appears to be a highly effective means of estradiol delivery similarly to sublingual estradiol.</p><p>It’s notable that at least one gender-affirming hormone therapy clinic, located in South Korea, uses sublingual estradiol valerate in transfeminine people. These clinicians have briefly described their experience with sublingual estradiol valerate and their rationale for using it over oral estradiol in a recent publication (<a href="https://doi.org/10.5468/ogs.2019.62.1.46">Lim et al., 2019</a>). While they don’t provide actual pharmacokinetic data on sublingual estradiol valerate (e.g., estradiol levels), it seems apparent based on their clinical experience that sublingual use is a therapeutically effective route of administration for this form of estradiol.</p><h2 id="formulation-of-estradiol-and-estradiol-valerate-tablets-and-implications-for-sublingual-use"> <a href="index.html#formulation-of-estradiol-and-estradiol-valerate-tablets-and-implications-for-sublingual-use" aria-labelledby="formulation-of-estradiol-and-estradiol-valerate-tablets-and-implications-for-sublingual-use" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Formulation of Estradiol and Estradiol Valerate Tablets and Implications for Sublingual Use</h2><h3 id="micronization-of-oral-estradiol-valerate-tablets"> <a href="index.html#micronization-of-oral-estradiol-valerate-tablets" aria-labelledby="micronization-of-oral-estradiol-valerate-tablets" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Micronization of Oral Estradiol Valerate Tablets</h3><p><a href="http://en.wikipedia.org/wiki/Micronization">Micronization</a> is a manufacturing process in which solid particles of a substance are reduced to smaller <a href="https://en.wikipedia.org/wiki/Particle_size">sizes</a>. Micronization can modify the pharmacokinetics of medications by altering their rate and extent of <a href="https://en.wikipedia.org/wiki/Absorption_(pharmacology)">absorption</a>. Oral estradiol tablets were originally non-micronized and had lower estrogenic <a href="https://en.wikipedia.org/wiki/Potency_(pharmacology)">potency</a> than those used today, but in the 1970s micronized oral estradiol tablets were introduced and replaced the previous formulations (<a href="https://en.wikipedia.org/wiki/Pharmacokinetics_of_estradiol#Absorption_and_bioavailability">Wiki</a>; <a href="https://en.wikipedia.org/wiki/Estradiol_(medication)#History">Wiki</a>). It appears that micronization of estradiol crystals to a defined particle size range improves the absorption and bioavailability of oral estradiol tablets by several-fold (<a href="https://en.wikipedia.org/wiki/Pharmacokinetics_of_estradiol#Absorption_and_bioavailability">Wiki</a>). All modern oral estradiol tablets available today are assumed to be micronized.</p><p>Questions arise as to what influence micronization has on sublingual administration (rather than oral administration) of hormonal agents like estradiol and estradiol valerate and whether oral estradiol valerate tablets are micronized similarly to oral estradiol tablets. The influence of micronization on the sublingual absorption and pharmacokinetic characteristics of estradiol and its esters, as well as other hormonal agents like <a href="http://en.wikipedia.org/wiki/Progesterone_(medication)">progesterone</a> and <a href="https://en.wikipedia.org/wiki/Testosterone_(medication)">testosterone</a>, does not seem to have been studied and hence is unknown. It could be assumed that micronization might improve the rate and extent of absorption with sublingual administration similarly to oral administration and hence may be important however, as touched on by the following literature excerpt (<a href="https://web.archive.org/web/20201111205841/https://www.pharmtech.com/view/considerations-developing-sublingual-tablets-overview">Sayeed &amp; Ashraf, 2014</a>):</p><blockquote><p>The drugs that are administered sublingually generally have low solubility. Therefore, to enhance dissolution, it is crucial to reduce and control the particle size of the [active pharmaceutical ingredient]. This attribute is important in the case of all drugs with low solubility. However, a tighter control on particle size of [active pharmaceutical ingredient] is desirable in sublingual drug products to maintain the reproducible quality and performance of the drug product in view of the limited window of dissolution and absorption time.</p></blockquote><p>As to whether oral estradiol valerate tablets are micronized, some formulations of oral estradiol valerate clearly indicate that they are micronized in their packaging or manufacturer information (<a href="https://archive.is/G3fYG">Photo</a>), whereas other formulations of oral estradiol valerate do not. The oral estradiol valerate tablets used in the study by Serhal and Craft (Progynova [Schering]) as well as certain other publications (e.g., <a href="https://doi.org/10.1093/humupd/4.6.856">Devroey &amp; Pados, 1998</a>) have been explicitly noted to be micronized. Considering the similar doses and apparently comparable clinical properties of all oral estradiol valerate tablets used today, it may be the case that all oral estradiol valerate formulations are micronized but that this simply isn’t always explicitly stated. Indeed, the original form of oral estradiol valerate introduced in the late 1960s is said to have been micronized (<a href="https://en.wikipedia.org/wiki/Estradiol_(medication)#History">Wiki</a>). An alternative but perhaps less likely possibility is that micronization might not influence the properties of oral estradiol valerate similarly to how it does with oral estradiol.</p><p>The University of California, San Francisco (UCSF) transgender care guidelines state that only micronized oral estradiol tablets can be used sublingually and imply that not all oral estradiol tablets are micronized (<a href="https://transcare.ucsf.edu/sites/transcare.ucsf.edu/files/Transgender-PGACG-6-17-16.pdf#page=26">Deutsch, 2016</a>). These statements may be assumed to also apply to oral estradiol valerate tablets. However, as discussed in this article, support for these notions is lacking at present.</p><h3 id="physicochemical-properties-of-estradiol-versus-estradiol-valerate"> <a href="index.html#physicochemical-properties-of-estradiol-versus-estradiol-valerate" aria-labelledby="physicochemical-properties-of-estradiol-versus-estradiol-valerate" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Physicochemical Properties of Estradiol versus Estradiol Valerate</h3><p>Estradiol valerate is more <a href="https://en.wikipedia.org/wiki/Lipophilicity">lipophilic</a> (fat-soluble) than estradiol due to its <a href="https://en.wikipedia.org/wiki/Fatty_acid">fatty acid</a> ester moiety (i.e., <a href="https://en.wikipedia.org/wiki/Valeric_acid">valeric acid</a>). Lipophilicity is known to modify the sublingual and buccal absorption of medications (<a href="https://doi.org/10.1517/17425247.2.3.507">Smart, 2005</a>; <a href="https://doi.org/10.1201/9781420004816-17">Batheja, Thakur, &amp; Michniak, 2006</a>). How the differing lipophilicities of estradiol versus estradiol valerate may influence their pharmacokinetics when used sublingually has not been studied. Hence, the therapeutic implications of this <a href="https://en.wiktionary.org/wiki/physicochemical">physicochemical</a> difference for this route are unknown. It’s also known however that esterases are present in the oral mucosa and saliva and can cleave <a href="https://en.wikipedia.org/wiki/Carboxylic_acid">carboxylic acid</a> esters like estradiol valerate into their unesterified forms (<a href="https://doi.org/10.1016/0169-409X(93)90039-7">Yamahara &amp; Lee, 1993</a>; <a href="https://doi.org/10.1016/0169-409X(94)90024-8">Rathbone, Drummond, &amp; Tucker, 1994</a>). This might serve to reduce the importance of the physicochemical differences between estradiol valerate and estradiol in terms of sublingual and buccal administration.</p><p>Another difference between estradiol and estradiol valerate is that estradiol valerate has a higher <a href="https://en.wikipedia.org/wiki/Molecular_weight">molecular weight</a> than estradiol due to its ester component and hence estradiol valerate contains less estradiol than estradiol for the same dose of substance. The molecular weight of estradiol valerate is about 131% of that of estradiol and hence estradiol valerate contains 76% of the estradiol as an equal amount of estradiol (<a href="https://en.wikipedia.org/wiki/Template:Structural_properties_of_selected_estradiol_esters">Table</a>). This difference has been shown to translate to pharmacokinetic studies of oral estradiol versus oral estradiol valerate, with estradiol levels being around 25% lower with oral estradiol valerate compared to oral estradiol at equal doses (<a href="https://en.wikipedia.org/wiki/Estradiol_valerate">Wiki</a>). This is likely also the case for other routes of administration of these forms of estradiol, including sublingual administration. Hence, slightly higher doses (e.g., 2 mg versus 1.5 mg) are likely needed and should be used for estradiol valerate relative to estradiol for equivalent estradiol levels and therapeutic estrogenic effect (<a href="../sublingual-e2-transfem/index.html">Sam, 2021</a>).</p><h3 id="formulation-and-dissolution-of-oral-estradiol-valerate-tablets"> <a href="index.html#formulation-and-dissolution-of-oral-estradiol-valerate-tablets" aria-labelledby="formulation-and-dissolution-of-oral-estradiol-valerate-tablets" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Formulation and Dissolution of Oral Estradiol Valerate Tablets</h3><p>Oral estradiol and estradiol valerate tablets were intended and designed for oral administration and not specifically for sublingual administration. Although many of these tablets do clearly work quite well when used sublingually, different tablet formulations vary in their <a href="https://en.wikipedia.org/wiki/Film_coating">coating</a> and their <a href="https://en.wikipedia.org/wiki/Chemical_composition">compositions</a> and <a href="https://en.wikipedia.org/wiki/Excipient">excipients</a>. It is possible that differences between formulations of these tablets may influence their properties when used sublingually, as touched on in the following literature excerpt (<a href="https://web.archive.org/web/20201111205841/https://www.pharmtech.com/view/considerations-developing-sublingual-tablets-overview">Sayeed &amp; Ashraf, 2014</a>):</p><blockquote><p>The conditions prevailing in the oral cavity for disintegration and dissolution of sublingual tablets are markedly different from the tablets that are orally ingested. […] Other specialized [oral] tablets, such as modified-release or enteric-coated tablets, may also partly release the drug in the stomach. In contrast, sublingual tablets are designed to completely disintegrate and dissolve in the oral cavity under the tongue.</p></blockquote><p>One particular issue is that different oral tablets of estradiol and estradiol valerate may dissolve at very different rates. One study of oral estradiol tablets used sublingually reported that they dissolved within 1 or 2 minutes (<a href="https://doi.org/10.1016/0002-9378(81)90101-0">Burnier, 1981</a>). Anecdotally this has been the case similarly with one brand of generic sugar-coated oral estradiol tablets in the United States (<a href="https://web.archive.org/web/20170716044325if_/http://img.medscapestatic.com/pi/features/drugdirectory/octupdate/BRR08870.jpg">Photo</a>), which dissolve and disappear sublingually within a few minutes at most. Some transfeminine people on social media sites like <a href="https://www.reddit.com/">Reddit</a> however have reported their tablets taking much longer to dissolve, for instance about an hour, when used sublingually or buccally. In any case, dissolution rates of oral estradiol and estradiol valerate tablets may vary depending on the formulation, and some forms of oral estradiol and oral estradiol valerate may be better-suited for sublingual use than others. If tablets take a long time to dissolve when used sublingually, switching to another brand may be considered.</p><h2 id="estradiol-or-estradiol-valerate-for-sublingual-use"> <a href="index.html#estradiol-or-estradiol-valerate-for-sublingual-use" aria-labelledby="estradiol-or-estradiol-valerate-for-sublingual-use" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Estradiol or Estradiol Valerate for Sublingual Use?</h2><p>Sublingual administration of oral estradiol tablets has been much better researched and characterized than sublingual administration of oral estradiol valerate tablets. Because of this, it may be advisable to select oral estradiol tablets with the intention of sublingual use over oral estradiol valerate tablets simply because there are fewer unknowns with them. However, oral estradiol tablets may not always be available in a given market, a person may be prescribed oral estradiol valerate tablets instead of oral estradiol tablets, or other considerations may make oral estradiol tablets a less feasible option. In this regard, it is clear based on available literature that sublingual estradiol valerate can be a highly effective means of delivering estradiol similarly to sublingual estradiol and can be used instead if needed.</p><h2 id="references"> <a href="index.html#references" aria-labelledby="references" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> References</h2><ul><li>Batheja, P., Thakur, R., &amp; Michniak, B. (2006). Basic Biopharmaceutics of Buccal and Sublingual Absorption. In Touitou, E., &amp; Barry, B. W. (Eds.). <em>Enhancement in Drug Delivery</em> (pp. 175–202). Boca Raton/London/New York: CRC Press. [<a href="https://scholar.google.com/scholar?cluster=8652202749142820648">Google Scholar</a>] [<a href="https://books.google.com/books?id=t0L_zFoXmjkC&amp;pg=PA175">Google Books</a>] [DOI:<a href="https://doi.org/10.1201/9781420004816-17">10.1201/9781420004816-17</a>]</li><li>Burnier, A. M., Martin, P. L., Yen, S. S., &amp; Brooks, P. (1981). Sublingual absorption of micronized 17β-estradiol. <em>American Journal of Obstetrics and Gynecology</em>, <em>140</em>(2), 146–150. [DOI:<a href="https://doi.org/10.1016/0002-9378(81)90101-0">10.1016/0002-9378(81)90101-0</a>]</li><li>Deutsch, M. B. (2016). Overview of feminizing hormone therapy. In Deutsch, M. B. (Ed.). <em>Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd Edition</em> (pp. 26–48). San Francisco: University of California, San Francisco/UCSF Transgender Care. [<a href="https://scholar.google.com/scholar?cluster=14884919836847089083">Google Scholar</a>] [<a href="https://transcare.ucsf.edu/guidelines/feminizing-hormone-therapy">URL</a>] [<a href="https://transcare.ucsf.edu/sites/transcare.ucsf.edu/files/Transgender-PGACG-6-17-16.pdf#page=26">PDF</a>]</li><li>Devroey, P., &amp; Pados, G. (1998). Preparation of endometrium for egg donation. <em>Human Reproduction Update</em>, <em>4</em>(6), 856–861. [DOI:<a href="https://doi.org/10.1093/humupd/4.6.856">10.1093/humupd/4.6.856</a>]</li><li>Lim, H. H., Jang, Y. H., Choi, G. Y., Lee, J. J., &amp; Lee, E. S. (2019). Gender affirmative care of transgender people: a single center’s experience in Korea. <em>Obstetrics &amp; Gynecology Science</em>, <em>62</em>(1), 46–55. [DOI:<a href="https://doi.org/10.5468/ogs.2019.62.1.46">10.5468/ogs.2019.62.1.46</a>]</li><li>Rathbone, M. J., Drummond, B. K., &amp; Tucker, I. G. (1994). The oral cavity as a site for systemic drug delivery. <em>Advanced Drug Delivery Reviews</em>, <em>13</em>(1–2), 1–22. [DOI:<a href="https://doi.org/10.1016/0169-409X(94)90024-8">10.1016/0169-409X(94)90024-8</a>]</li><li>Sam. (2021). An Exploration of Sublingual Estradiol as an Alternative to Oral Estradiol in Transfeminine People. <em>Transfeminine Science</em>. [<a href="../sublingual-e2-transfem/index.html">URL</a>]</li><li>Sayeed, V. A., &amp; Ashraf, M. (2014). Considerations in Developing Sublingual Tablets—An Overview. <em>Pharmaceutical Technology</em>, <em>38</em>(11), 34–72. [<a href="https://scholar.google.com/scholar?cluster=1357039233409295184">Google Scholar</a>] [<a href="https://web.archive.org/web/20201111205841/https://www.pharmtech.com/view/considerations-developing-sublingual-tablets-overview">URL</a>] [<a href="../../../files.transfemscience.org/pdfs/Sayeed&#32;&amp;&#32;Ashraf&#32;(2014)&#32;-&#32;Considerations&#32;in&#32;Developing&#32;Sublingual&#32;Tablets—An&#32;Overview&#32;-&#32;Pharmaceutical&#32;Technology.pdf">PDF</a>]</li><li>Serhal, P., &amp; Craft, I. (1989). Oocyte donation in 61 patients. <em>The Lancet</em>, <em>333</em>(8648), 1185–1187. [DOI:<a href="https://doi.org/10.1016/S0140-6736(89)92762-1">10.1016/S0140-6736(89)92762-1</a>]</li><li>Serhal, P. (1990). Oocyte donation and surrogacy. <em>British Medical Bulletin</em>, <em>46</em>(3), 796–812. [DOI:<a href="https://doi.org/10.1093/oxfordjournals.bmb.a072432">10.1093/oxfordjournals.bmb.a072432</a>]</li><li>Smart, J. D. (2005). Buccal drug delivery. <em>Expert Opinion on Drug Delivery</em>, <em>2</em>(3), 507–517. [DOI:<a href="https://doi.org/10.1517/17425247.2.3.507">10.1517/17425247.2.3.507</a>]</li><li>Yamahara, H., &amp; Lee, V. H. (1993). Drug metabolism in the oral cavity. <em>Advanced Drug Delivery Reviews</em>, <em>12</em>(1–2), 25–39. [DOI:<a href="https://doi.org/10.1016/0169-409X(93)90039-7">10.1016/0169-409X(93)90039-7</a>]</li></ul></div></div><div id="footer"> <span id="footer-subcontainer"> <span id="site-copyright">&copy; 2026 <span translate="no" class="notranslate">Transfeminine Science</span></span> </span></div></div></body></html>